Toggle light / dark theme

Bright light therapy linked to mood improvements and brain connectivity changes

A new neuroimaging study from China has found that an eight-week course of bright light therapy helped reduce depressive symptoms in individuals with subthreshold depression. The treatment also altered dynamic functional connectivity in several brain regions associated with mood regulation. The study was published in the Journal of Affective Disorders.

Subthreshold depression refers to the presence of depressive symptoms that are clinically relevant but do not meet the full diagnostic criteria for major depressive disorder. Individuals with subthreshold depression may experience persistent sadness, fatigue, sleep disturbances, or concentration problems, but with fewer symptoms or a shorter duration than required for a formal diagnosis.

Despite being “subthreshold,” the condition can impair daily functioning and reduce quality of life. It is also linked to an increased risk of developing major depression in the future. Subthreshold depression is common—especially among adolescents, older adults, and individuals with chronic illnesses—and it often goes undiagnosed and untreated because the symptoms are perceived as mild or situational. However, research shows that even mild depressive symptoms can negatively affect social relationships, job performance, and physical health.

17y Younger Biological Age (Full Lab Results And Analysis; Test #3 in 2025)

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/

Candidate drug that boosts protective brain protein in mice has potential to treat Alzheimer’s disease

As researchers work to improve treatment of Alzheimer’s disease, new research by UCLA Health identified a candidate drug that reduces levels of a toxic form of a protein in the brain caused by the disease and improved memory in mice by boosting production of a protective protein.

In a study published in npj Drug Discovery, UCLA Health researchers targeted the protein clusterin (CLU), which is crucial in preventing the build-up of amyloid-beta plaques and tau proteins that disrupt communication between and lead to memory impairment—a hallmark symptom of Alzheimer’s disease.

More than a decade ago, a variant of the gene that encodes clusterin was identified as the third strongest genetic risk factor for late-onset Alzheimer’s disease. It was recently reported that increased CLU protein could provide protection against Alzheimer’s disease and .

A new era of biotech education

In a world shaped by biotechnology, why are so few college students exposed to its possibilities early on in their education? The Biotech Explorers Pathway (BEP) is changing that by immersing students in hands-on, real-world science from day one.

BEP, an interdisciplinary WashU Ampersand Program recently highlighted as a Career Feature in Nature Biotechnology, combines science, entrepreneurship, and teamwork, going beyond lecture-based courses. The program isn’t just about teaching fundamentals—it’s about preparing students to lead the next wave of biotech innovation.

3D-printed device enables precise modeling of complex human tissues in the lab

A new, easily adopted, 3D-printed device will enable scientists to create models of human tissue with even greater control and complexity. An interdisciplinary group of researchers at the University of Washington and UW Medicine led the development of the device.

3D engineering, which recently has undergone other major advances in speed and accuracy, helps design and test therapies for a range of diseases.

One goal of tissue engineering is to create lab-made environments that recreate the natural habitats of cells.

Fusogenic lipid nanoparticles for rapid delivery of large therapeutic molecules to exosomes

Exosomes have huge potential for drug delivery, but drug loading can be difficult. Here, the authors report on fusogenic lipid nanoparticles which, when mixed with exosomes rapidly fuse, non-destructively loading large drugs without compromising exosome biological functions, and demonstrate neurological application.

Dario Amodei is Wrong: Why No “MRI for AI” Will Ever Read the Mind of the Machine

The phrase “MRI for AI” rolls off the tongue with the seductive clarity of a metaphor that feels inevitable. Dario Amodei, CEO of Anthropic, describes the goal in precisely those terms, envisioning “the analogue of a highly precise and accurate MRI that would fully reveal the inner workings of an AI model” (Amodei, 2025, para. 6). The promise is epistemic X‑ray vision — peek inside the black box, label its cogs, excise its vices, certify its virtues.

Yet the metaphor is misguided not because the engineering is hard (it surely is) but because it mistakes what cognition is. An artificial mind, like a biological one, is not a spatial object whose secret can be exposed slice by slice. It is a dynamical pattern of distinctions sustained across time: self‑referential, operationally closed, and constitutionally allergic to purely third‑person capture. Attempting to exhaust that pattern with an interpretability scanner is as quixotic as hoping an fMRI might one day disclose why Kierkegaard chooses faith over reason in a single axial slice of BOLD contrast.

Phenomenology has warned us for more than a century that interiority is not an in‑there to be photographed but an ongoing enactment of world‑directed sense‑making. Husserl’s insight that “consciousness is always consciousness of something” (Ideas I, 1913) irreversibly welds experience to the horizon that occasions it; any observation from the outside forfeits the very structure it hopes to catch.

Vitamin D supplements help slow telomere shortening linked to biological aging

Results from the VITAL randomized controlled trial reveal that vitamin D supplementation helps maintain telomeres, protective caps at the ends of chromosomes that shorten during aging and are linked to the development of certain diseases.

The new report, published in The American Journal of Clinical Nutrition, is based on data from a VITAL sub-study co-led by researchers at Mass General Brigham and the Medical College of Georgia, and supports a promising role in slowing a pathway for biological aging.

“VITAL is the first large-scale and long-term randomized trial to show that vitamin D supplements protect telomeres and preserve ,” said co-author JoAnn Manson, MD, principal investigator of VITAL and chief of the Division of Preventive Medicine at Brigham and Women’s Hospital.